SANTA BARBARA, Calif.--(EON: Enhanced Online News)--QAD Inc. (NASDAQ:QADA) (NASDAQ:QADB) announced today it has seen increased deployments among Medical Technology (Medtech) manufacturers for QAD On Demand Life Sciences Edition, the cloud enterprise resource planning (ERP) solution. QAD On Demand is full-strength cloud ERP that makes it easier for Medtech to meet globalization challenges and allocate capital for business initiatives and product innovation.
“Globalization has transformed demand for medical technology, accelerated production processes and given rise to new economies”
“Globalization has transformed demand for medical technology, accelerated production processes and given rise to new economies,” said Dave Medina, vice president of Life Sciences at QAD. “To meet today’s globalization challenges and opportunities, Medtech manufacturers are moving to the QAD global cloud ERP to benefit from its simplicity, reliability, global capabilities and predictable cost structure.”
QAD Cloud ERP Lets Medtech Focus on their Business and Product Innovation
QAD On Demand Life Sciences Edition offers the full suite of ERP capabilities and specific life sciences services to help QAD customers meet regulatory compliance. QAD cloud ERP allows Medtech manufacturers to focus on their business initiatives and product innovation – not their ERP software. The QAD cloud ERP model enables customers to eliminate capital expenditures associated with premise-based ERP software, hardware, system maintenance and support. QAD On Demand offers a robust and highly available solution. It is particularly scalable – and allows companies to standardize their ERP as they acquire new divisions, divest or pursue opportunities to rapidly scale operations in growth markets. QAD global capabilities with built-in support for local languages, currencies, business practices and legal requirements, enable Medtech manufacturers to efficiently align their global operations to strategic goals and perform at their best.
QAD Fully Qualified Cloud ERP – Built For Medical Technology Manufacturers
With QAD’s fully qualified IT environment and validation support tools, Medtech manufacturers can reduce the costs and effort of complying with regulatory requirements for software validation. QAD Life Science On Demand offers all the robust capabilities of QAD On Demand, but provides the necessary standard operating procedures (SOPs) required to meet requirements of the Food and Drug Administration (FDA), current Good Manufacturing Practices (cGMP) and 21 CFR Part 11.
Enhanced quality control capabilities in the QAD solution enhance product integrity across the global supply network -- from sourcing raw materials to distributing finished products -- with backward and forward traceability. This is particularly important for achieving regulatory requirements such as the emerging requirements for Unique Device Identification (UDI) compliance.
QAD Easy On Boarding Process Maps Support Compliance
QAD works closely with its customers to build a clear and pragmatic implementation plan to move their ERP to the cloud. The QAD solution is delivered using QAD Easy On Boarding process maps for life sciences with embedded support to meet cGMP requirements. This ensures that QAD implementations meet regulatory requirements.
Medtech Can Move their ERP to Cloud with Flexible Deployment Options
QAD offers flexible deployment options that allow customers with existing ERP software to blend deployment of ERP in the public cloud and on premise. Customers can run instances of QAD On Premise, QAD On Demand, or a blended deployment option of both QAD On Demand and QAD On Premise at different sites, simultaneously. Customers benefit from the same functionality, business processes, internationalizations and user experience across QAD Enterprise Applications regardless of the deployment model.
“Medical device and diagnostic manufacturers ranging from start-ups to multinationals are increasingly selecting QAD Life Sciences on Demand to transform globalization challenges into opportunities for business growth and innovation,” added Medina. “We’re focused on helping medical technology manufacturers become more Effective Enterprises and achieve their goals to produce and deliver innovative, safe and effective healthcare products.”
For more information about QAD Life Sciences On Demand, please visit: http://www.qad.com/on-demand-software.
QAD Inc. (NASDAQ: QADA) (NASDAQ: QADB), is a leading provider of enterprise software and services designed exclusively for global manufacturing companies. For more than 30 years, QAD has provided global manufacturing companies with an enterprise resource planning (ERP) system that supports operational requirements; including financials, manufacturing, demand and supply chain planning, customer management, business intelligence and business process management. QAD offers flexible deployment options: QAD On Premise software and QAD On Demand software-as-a-service. Customers can operate in a blended environment where some users can be deployed On Premise and some users deployed via On Demand while offering the same end-user experience. With QAD, customers and partners in the automotive, consumer products, food and beverage, high technology, industrial products and life sciences industries can better align daily operations with their strategic goals to meet their vision of becoming more Effective Enterprises.
For more information about QAD, telephone +1 805-566-6000, visit www.qad.com.
“QAD” is a registered trademark of QAD Inc. All other products or company names herein may be trademarks of their respective owners.
Note to Investors: This press release contains certain forward-looking statements made under the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expects”, “believes”, “anticipates”, “could”, “will likely result”, “estimates”, “intends”, “may”, “projects”, “should”, and variations of these words and similar expressions are intended to identify these forward looking statements. Forward-looking statements are based on the company’s current expectations and assumptions regarding its business, the economy and future conditions. A number of risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements. These risks include, but are not limited to, evolving demand for the company's software products and products that operate with the company's products; the company's ability to sustain license and service demand; the company's ability to leverage changes in technology; the company's ability to sustain customer renewal rates at current levels; the publication of opinions by industry and financial analysts about the company, its products and technology; the reliability of estimates of transaction and integration costs and benefits; the entry of new competitors or new offerings by existing competitors and the associated announcement of new products and technological advances by them; delays in localizing the company's products for new or existing markets; the ability to recruit and retain key personnel; delays in sales as a result of lengthy sales cycles; changes in operating expenses, pricing, timing of new product releases, the method of product distribution or product mix; timely and effective integration of newly acquired businesses; general economic conditions; exchange rate fluctuations; and, the global political environment. In addition, revenue and earnings in the enterprise resource planning (ERP) software industry are subject to fluctuations. Software license revenue, in particular, is subject to variability with a significant proportion of revenue earned in the last month of each quarter. Given the high margins associated with license revenue, modest fluctuations can have a substantial impact on net income. Investors should not use any one quarter's results as a benchmark for future performance. For a more detailed description of the risk factors associated with the company and the industries in which it operates, please refer to the company's Annual Report on Form 10-K for fiscal 2013 ended January 31, 2013, and in particular, the section entitled “Risk Factors” therein, and in other periodic reports the company files with the Securities and Exchange Commission.